Swiss National Bank Grows Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Swiss National Bank raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 57.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,700 shares of the company's stock after purchasing an additional 37,800 shares during the period. Swiss National Bank owned approximately 0.15% of Replimune Group worth $1,256,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REPL. Intech Investment Management LLC acquired a new position in Replimune Group in the 3rd quarter valued at approximately $252,000. Charles Schwab Investment Management Inc. increased its position in shares of Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock worth $5,313,000 after buying an additional 52,498 shares during the period. The Manufacturers Life Insurance Company boosted its position in Replimune Group by 24.9% during the third quarter. The Manufacturers Life Insurance Company now owns 184,208 shares of the company's stock valued at $2,019,000 after acquiring an additional 36,689 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock worth $165,000 after acquiring an additional 6,748 shares in the last quarter. Finally, MetLife Investment Management LLC grew its stake in Replimune Group by 21.5% during the third quarter. MetLife Investment Management LLC now owns 35,134 shares of the company's stock worth $385,000 after purchasing an additional 6,216 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Remove Ads

Replimune Group Stock Performance

Shares of REPL stock traded down $0.64 on Monday, hitting $9.75. 913,431 shares of the stock were exchanged, compared to its average volume of 858,501. The firm's 50 day moving average is $12.67 and its two-hundred day moving average is $12.17. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The firm has a market capitalization of $750.90 million, a PE ratio of -3.18 and a beta of 1.30. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Sell-side analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on REPL shares. BMO Capital Markets raised their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.